Document:

Exhibit
      10.4

    Amendment
      No. 1 to

    

    EMPLOYMENT
      AGREEMENT

     

    This
      Amendment No. 1 (the “Amendment”) made this 19th day of August, hereby amends
      that certain EMPLOYMENT AGREEMENT (the “Agreement”)
      dated
      January 19, 2007, by and between NILE PHARMACEUTICALS, INC., a Delaware
      corporation with principal executive offices at 2850 Telegraph Ave., Berkeley,
      CA 94704 (the “Company”),
      and
      MR. DARON EVANS, residing at 3029
      Riverside Avenue, Jacksonville, FL 32205 (the“Executive”).
      Capitalized terms used herein but not otherwise defined shall have the meaning
      ascribed to such terms in the Agreement.

     

    The
      Agreement is hereby amended as follows:

     

    1.  Note
      Repayment Bonus.
      The
      Company shall pay to you a bonus (the “Performance Bonus”) in the amount of
      $64,969.41, which you agree to use to repay $47,785.00 to the Company,
      representing the principal amount and all accrued but unpaid interest on the
      Note described in Section 3(g) of the Agreement. The Company shall withhold
      all
      applicable taxes related to the Note Repayment Bonus.

     

    2.  Performance
      Bonus.The
      Performance Bonus shall be amended to provide that the Executive shall be
      eligible to receive a proportionate share (based on the assigned weight of
      each
      of the Performance Milestones (as defined below) of $28,344 upon the successful
      completion of annual corporate or individual Performance Milestones at the
      “Realistic” metric. If Performance Milestones are achieved at the “Stretch”
metric, the Company shall pay you a proportionate share of $38,344.

     

    IN
      WITNESS WHEREOF, the parties hereto have executed this Amendment as of the
      date
      first above written.

     

    
      	
              NILE
                THERAPEUTICS, INC.

            
	 	 	 
	
              By:

            	
              /s/
                Peter M. Strumph

            	 
	
              Name:

            	
              Mr.
                Peter M. Strumph

            
	
              Title:

            	
              Chief
                Executive Officer

            
	 	 	 
	
              EXECUTIVE

            
	 	 	 
	
              By:
                

            	
              /s/
                Daron Evans

            	 
	
              Name:

            	
              Mr.
                Daron EvansUnassociated Document

     

    Exhibit
      10.5

    August
      7,
      2007

    

    Ms.
      Jennifer Hodge

    812C
      Lyon
      Street

    San
      Francisco, CA 94115

    

    Dear
      Ms.
      Hodge:

    

    We
      are
      pleased to offer you the position of Vice President of Clinical Development
      for
      Nile Therapeutics, Inc. (“Nile”). This letter (the “Letter”) sets forth the
      proposed terms of your employment with Nile:

    

    
      	 	
              1.

            	
              You
                shall serve as Vice
                President of Clinical Development of
                Nile and shall have such powers and perform such duties as are customarily
                performed by the Vice
                President of Clinical Development.
                You
                shall report directly to Chief Financial
                Officer.

            

    

    

    
      	 	
              2.

            	
              You
                shall receive an annual base salary equal to One Hundred Seventy
                Thousand
                Dollars ($170,000), payable in accordance with Nile’s payroll
                practices.

            

    

    

    
      	 	
              3.

            	
              You
                will receive an annual bonus of up to 30% of your base salary based
                upon
                the successful accomplishment of individual and corporate performance
                goals to be agreed upon annually between you and the Chief Executive
                Officer of Nile, which amount shall be pro-rated for the year 2007.
                Any
                performance bonus shall be payable on or about December 31st
                of
                each year. 

            

    

    

    
      	 	
              4.

            	
              Nile
                shall grant to you stock options pursuant to the Company’s 2005 Stock
                Option Plan (the “Employment Options”) immediately after the closing of
                the next round of financing to purchase that number of shares representing
                one percent (1%) of the outstanding common stock of the Company,
                par value
                $0.001 per share (the “Common Stock”), on a fully diluted basis as of the
                grant date.
                The Employment Options shall have an
                exercise price equal to Fair Market Value (as determined the Company’s
                2005 Stock Plan) (the “Exercise Price”) of
                a share of Common Stock on the date of grant.
                The
                Employment Options shall be subject to the terms and conditions of
                the
                Plan and
                shall vest and become exercisable in accordance with the following
                schedule: 

            

    

    

    
      	 	
              a.

            	
              25%
                of the Employment Options shall become exercisable on the first
                anniversary of the Effective Date; and

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	 	
              b.

            	
              thereafter,
                2 and 1/12% of the Employment Options shall become exercisable on
                the last
                day of each calendar month until all remaining Employment Options
                are
                fully vested and exercisable (each date on which Employment Options
                vest
                is hereinafter referred to as a "Vesting Date").
                

            

    

    

    
      	 	
              c.

            	
              For
                purposes of this Agreement, “Fully Diluted Basis” shall
                mean the number of shares of Common Stock that would be outstanding
                upon
                the conversion of all outstanding shares of preferred stock of the
                Company
                (the “Preferred Stock”) outstanding at the grant date, plus the shares of
                Common Stock issuable upon conversion or exercise, as the case may
                be, of
                all securities of the Company convertible into, exercisable for,
                or
                exchangeable for, directly or indirectly, shares of Common Stock,
                which
                are currently exercisable by the holder thereof or which will become
                exercisable within 90 days of the grant
                date.

            

    

    

    
      	 	
              5.

            	
              In
                the event that Nile acquires by license, acquisition or otherwise,
                an
                additional biotechnology product for development that is first identified
                by you, then Nile shall grant to you options (the “Technology Options”) to
                purchase a number of shares of Common Stock as follows:
                

            

    

    

    
      	 	
              a.

            	
              One-half
                percent (0.5%) of the then Fully Diluted Outstanding shares of Common
                Stock of the Company for a product that is in pre-clinical development;
                and 

            

    

    

    
      	 	
              b.

            	
              One
                percent (1%) of the then Fully Diluted Outstanding shares of Common
                Stock
                of the Company for a product that is in human clinical
                trials.

            

    

    

    The
      Technology Options shall have an exercise price equal to the fair market value
      of Nile’s Common Stock as of the date of the granting of the Technology Options,
      and shall be exercisable for a period of five (5) years.

    

    
      	 	
              6.

            	
              Nile
                will reimburse you for all normal, usual and necessary expenses incurred
                in furtherance of the business and affairs of Nile, including reasonable
                travel and entertainment, upon timely receipt by Nile of appropriate
                vouchers or other proof of your expenditures and otherwise in accordance
                with any expense reimbursement policy as may from time to time be
                adopted
                by Nile.

            

    

     

    
      	 	
              7.

            	
              You
                shall be entitled to four (4) weeks of vacation, sick and personal
                days
                per year.

            

    

    

    
      	 	
              8.

            	
              Your
                employment will be on an at-will basis and shall commence on August
                31,
                2007, or such other time as may be agreed to by you and
                Nile.

            

    

    

    
      	 	
              9.

            	
              You
                shall be entitled to participate in the group medical policy of Nile.
                Nile
                will pay for health and dental insurance premiums for you at the
                basic
                level insurance plan. Should you desire to enroll in the higher insurance
                plan, you will be responsible for the payment of the difference in
                premium
                costs between the two plans. You shall be entitled to participate
                in any
                other benefits made available to employees of
                Nile.

            

    

    

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    

    
      	 	
              10.

            	
              Confidentiality.

            

    

    

    
      	 	
              a.

            	
              You
                recognize and acknowledge that in the course of your duties you are
                likely
                to receive confidential or proprietary information owned by Nile,
                its
                affiliates or third parties with whom Nile or any such affiliates
                has an
                obligation of confidentiality. Accordingly, during and after the
                Term, you
                agree to keep confidential and not disclose or make accessible to
                any
                other person or use for any other purpose other than in connection
                with
                the fulfillment of your duties under this Agreement, any Confidential
                and
                Proprietary Information (as defined below) owned by, or received
                by or on
                behalf of, Nile or any of its affiliates. “Confidential and Proprietary
                Information” shall include, but shall not be limited to, confidential or
                proprietary scientific or technical information, data, formulas and
                related concepts, business plans (both current and under development),
                client lists, promotion and marketing programs, trade secrets, or
                any
                other confidential or proprietary business information relating to
                development programs, costs, revenues, marketing, investments, sales
                activities, promotions, credit and financial data, manufacturing
                processes, financing methods, plans or the business and affairs of
                Nile or
                of any affiliate or client of Nile. You expressly acknowledge the
                trade
                secret status of the Confidential and Proprietary Information and
                that the
                Confidential and Proprietary Information constitutes a protectable
                business interest of Nile. You agree: (i) not to use any such
                Confidential and Proprietary Information for strictly personal use
                or for
                others; and (ii) not to permanently remove any Company material or
                reproductions (including but not limited to writings, correspondence,
                notes, drafts, records, invoices, technical and business policies,
                computer programs or disks) thereof from Nile’s offices at any time during
                your employment by Nile, except as required in the execution of your
                duties to Nile, provided; however, that you shall not be prevented
                from
                using or disclosing any Confidential and Proprietary
                Information:

            

    

    

    
      	 	
              i.

            	
              that
                you can demonstrate was known to her prior to the effective date
                of that
                certain Confidential Disclosure Agreement entered into between the
                Parties
                dated July 10, 2007; 

            

    

    

    
      	 	
              ii.

            	
              that
                is now, or becomes in the future, available to persons who are not
                legally
                required to treat such information as confidential unless such persons
                acquired the Confidential and Proprietary Information through acts
                or
                omissions by you; 

            

    

    

    
      	 	
              iii.

            	
              that
                is within your general business or industry knowledge, know-how or
                expertise; or 

            

    

    

    
      	 	
              iv.

            	
              that
                you are compelled to disclose pursuant to the order of a court or
                other
                governmental or legal body having jurisdiction over such
                matter.

            

    

    

    
      	 	
              b.

            	
              You
                agree to return immediately all Company material and reproductions
                (including but not limited, to writings, correspondence, notes, drafts,
                records, invoices, technical and business policies, computer programs
                or
                disks) thereof in your possession to Nile upon request and in any
                event
                immediately upon termination of
                employment.

            

    

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    
      	 	
              c.

            	
              Except
                with prior written authorization by Nile, you agree not to disclose
                or
                publish any of the Confidential and Proprietary Information, or any
                confidential, scientific, technical or business information of any
                other
                party to whom Nile or any of its affiliates owes a legal duty of
                confidence, at any time during or after your employment with
                Nile.

            

    

    

    
      	 	
              d.

            	
              You
                agree that all inventions, discoveries, improvements and patentable
                or
                copyrightable works, relating to Nile’s Business (as defined below).
                (“Inventions”) initiated, conceived or made by him, either alone or in
                conjunction with others, during the Term shall be the sole property
                of
                Nile to the maximum extent permitted by applicable law and, to the
                extent
                permitted by law, shall be “works made for hire” as that term is defined
                in the United States Copyright Act (17 U.S.C.A., Section 101). For
                purposes of this Agreement, “Company’s Business”
                shall be the development of novel therapeutics for the treatment
                of
                cardiovascular disease and in the future, any other business in which
                it
                actually devotes substantive resources to study, develop or pursue.
                Nile
                shall be the sole owner of all patents, copyrights, trade secret
                rights,
                and other intellectual property or other rights in connection therewith.
                You hereby assign to Nile all right, title and interest you may have
                or
                acquire in all such Inventions; provided; however, that the Board
                of
                Directors of Nile may in its sole discretion agree to waive Nile’s rights
                pursuant to this section with respect to any Invention that is not
                directly or indirectly related to Nile’s business. You further agree to
                assist Nile in every proper way (but at Nile’s expense) to obtain and from
                time to time enforce patents, copyrights or other rights on such
                Inventions in any and all countries, and to that end you will execute
                all
                documents necessary:

            

    

    

    
      	 	
              i.

            	
              to
                apply for, obtain and vest in the name of Nile alone (unless Nile
                otherwise directs) letters patent, copyrights or other analogous
                protection in any country throughout the world and when so obtained
                or
                vested to renew and restore the same;
                and

            

    

    

    
      	 	
              ii.

            	
              to
                defend any opposition proceedings in respect of such applications
                and any
                opposition proceedings or petitions or applications for revocation
                of such
                letters patent, copyright or other analogous
                protection.

            

    

    

    
      	 	
              e.

            	
              You
                acknowledge that while performing the services under this Agreement
                you
                may locate, identify and/or evaluate patented or patentable inventions
                having commercial potential in the fields of pharmacy, pharmaceutical,
                biotechnology, healthcare, technology and other fields which may
                be of
                potential interest to Nile or one of its affiliates (the “Third Party
                Inventions”). You understand, acknowledge and agree that all rights to,
                interests in or opportunities regarding, all Third-Party Inventions
                identified by Nile, any of its affiliates or either of the foregoing
                persons’ officers, directors, employees (including you), agents or
                consultants during the Term shall be and remain the sole and exclusive
                property of Nile or such affiliate and you shall have no rights whatsoever
                to such Third-Party Inventions and will not pursue for himself or
                for
                others any transaction relating to the Third-Party Inventions which
                is not
                on behalf of Nile.

            

    

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    
      	 	
              f.

            	
              The
                provisions of this Section 10 shall survive any termination of your
                employment.

            

    

     

    If
      you
      find the foregoing arrangement acceptable, kindly sign where appropriate and
      return a copy of this Letter to me.

     

    
      	 	Very
              truly yours,	 
	 	 	 
	 	By:	/s/
              Peter M. Strumph	 
	 	Name: Mr.
              Peter M. Strumph	 
	 	Title: President	 

    

    

    Agreed
      and Accepted:

     

    
      	By:	/s/
              Jennifer Hodge	 
	Name:
              Ms. Jennifer Hodge	 
	Date:
              August 7, 2007	 

    

    

    
      
        
        

      

      
        5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]